Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

The achievement of pathologic complete response (pCR) is strongly prognostic for event-free survival (EFS) and overall survival (OS) in patients with early breast cancer (EBC), and adapting postneoadjuvant therapy improves long-term outcomes for patients with HER2-positive disease not achieving pCR....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2023-06, Vol.41 (16), p.2998-3008
Hauptverfasser:	van Mackelenbergh, Marion T, Loibl, Sibylle, Untch, Michael, Buyse, Marc, Geyer, Jr, Charles E, Gianni, Luca, Schneeweiss, Andreas, Conte, Pierfranco, Piccart, Martine, Bonnefoi, Herve, Jackisch, Christian, Nekljudova, Valentina, Tang, Gong, Valagussa, Pinuccia, Neate, Colin, Gelber, Richard, Poncet, Coralie, Squifflet, Pierre, Saad, Everardo D, Heinzmann, Dominik, Denkert, Carsten, Rastogi, Priya, Cortes, Javier, Guarneri, Valentina, de Azambuja, Evandro, Cameron, David, Ismael, Gustavo, Wolmark, Norman, Cortazar, Patricia
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - pathology Disease-Free Survival Female Hormones - therapeutic use Humans Neoadjuvant Therapy Prognosis Receptor, ErbB-2 - metabolism Trastuzumab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!